Gantenerumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Beta-amyloid (Aβ40/42) |
| Clinical data | |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
1043556-46-2  |
| ChemSpider | none |
| UNII |
4DF060P933  |
| KEGG |
D09680 |
| Chemical and physical data | |
| Formula | C6496H10072N1740O2024S42 |
| Molar mass | 146.3 kg/mol (peptide) |
| (what is this?) (verify) | |
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3]
Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries. [4]
One clinical study was stopped on December 19, 2014 after disappointing results.[5]
As of late 2014, Phase III clinical trials are ongoing.[6]
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
- ↑ Clinical trial number NCT00531804 for "A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease" at ClinicalTrials.gov
- ↑ http://www.scarletroadstudy.com/en-CA/index.aspx
- ↑ http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045
- ↑ H. Spreitzer (10 November 2014). "Neue Wirkstoffe – Gantenerumab". Österreichische Apothekerzeitung (in German) (23/2014): 55.
This article is issued from Wikipedia - version of the 10/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.